April 10, 2020

To the Office of Attorney General:

On September 9, 2019, Nabriva Therapeutics US, Inc. ("Nabriva") introduced the following drugs into the market:

NDC Number	Drug Product Description
72000-0110-30	XENLETA 600MG/1 30 TAB 1 BOTTLE

Pursuant to 18 V.S.A. §4637(c), Nabriva provides the following additional product information listed below.

1. US and international marketing and pricing plans used at launch
    a. Because this information is not in the public domain or publicly available and is confidential, Nabriva declines to provide this information in accordance with 18 V.S.A. §4637(d).

2. Estimated volume of patients
    a. The estimated number of patients who may be prescribed XENLETA is not in the public domain, not publicly available, and is confidential. Additionally, Nabriva does not have any information on the estimated volume of patients.

3. Whether the FDA granted breakthrough therapy designation or priority review
    a. Neither breakthrough therapy designation nor priority review was granted by the FDA.

4. Date and price of acquisition
    a. This is inapplicable – Nabriva did not acquire the product from another manufacturer.

Please feel free to contact me if you have any questions and/or require any additional information.

Michelle Urban,
Director, Pricing & Contracting
Michelle.Urban@Nabriva.com